ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

‘Major Discover’ At FCRDC Is NF1 Gene, Report Says

November 30, 1990

Targeting One Specific Protein Can Double PFS; Triple Overall Survival

May 27, 2011

NCI-Approved Clinical Trials

February 23, 2007

Rogers Reaffirms Congress’ Interest In Cancer Program; Act Renewal To “Broaden, Sustain It”

April 14, 1978

Judge Declines To Issue Injunction To Stop Amgen’s “Bundling.”

December 1, 2006

AGS-003 Increased Survival In Combination with Sunitinib

February 24, 2012